 Outlook Therapeutics NASDAQ:OTLK Inc has provided an update on its Biologics License Application BLA submission for ONS-5010LYTENAVA bevacizumab-vikg for the treatment of wet age-related macular degeneration wet AMD. The pre-commercial biopharmaceutical company said it has confirmed the additional information necessary to re-submit the BLA for ONS-5010 by September 2022 following receipt of additional correspondence from the US Food and Drug Administration FDA. 